The development of ultrathin strut drug eluting stents (DES) was initiated to overcome potential drawbacks of early generation DES. The Orsiro (Biotronik, Berlin, Germany) sirolimus-eluting stent (SES) is a hybrid DES consisting of passive and active components. Its characteristics have been described in detail previously .